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Abstract
Background: Active tuberculosis (TB) disease can impose substantial morbidity, while treatment for latent TB
infection (LTBI) has frequent side effects. We compared health-related quality of life (HRQOL) between persons
diagnosed and treated for TB disease, persons treated for LTBI, and persons screened but not treated for TB disease
or LTBI, over one year following diagnosis/initial assessment.
Methods: Participants were recruited at two hospitals in Montreal (2008–2011), and completed the Short Form-36
version 2 (SF-36) at baseline, and at 1, 2, 4, 6, 9, and 12 months thereafter. Eight domain scores and physical and
mental component summary (PCS and MCS, respectively) scores were calculated from responses. Linear mixed
models were used to compare mean scores at each evaluation and changes in scores over consecutive evaluations,
among participants treated for TB disease and those treated for LTBI, each compared to the control group.
Results: Of the 263 participants, 48 were treated for TB disease, 105 for LTBI, and 110 were control participants.
Fifty-four percent were women, mean age was 35 years, and 90% were foreign-born. Participants treated for TB
disease reported significantly worse mean scores at baseline compared to control participants (mean PCS scores:
50.0 vs. 50.7; mean MCS scores: 46.4 vs. 51.1), with improvement in mean MCS scores throughout the study period.
Scores reported by participants treated for LTBI and control participants were comparable throughout the study.
Conclusion: TB disease is associated with decrements in HRQOL as measured by the SF-36. This is most
pronounced during the weeks after diagnosis and treatment initiation, but is no longer evident after two months.
Keywords: Tuberculosis, Health-related quality of life, SF-36, Linear mixed model regression
Background
Individuals diagnosed with tuberculosis (TB) disease report
notable decrements in health-related quality of life
(HRQOL), in relation to both physical and psychological
well-being [1,2]. Treatment typically requires a combination
of 4 drugs in the initial phase, with a minimum treatment
period of 6 months [3]. Treatment guidelines recommend a
patient-centered approach to address both medical and psy-
chological needs of patients with TB disease [4].
In high-income countries, like Canada, many patients
diagnosed with latent TB infection (LTBI) receive treat-
ment. This treatment usually involves isoniazid (INH)
taken daily for 9 months; treatment completion is often
hampered by drug intolerance and inconvenient treat-
ment and clinic visit schedules [5,6].
An overwhelming majority of individuals screened and
treated for LTBI and TB disease in high-income coun-
tries are recent immigrants [3,7,8]. A key challenge of
research describing HRQOL of patients treated for LTBI
and TB disease is to tease apart the impact of diagnosis
and treatment from that of typical stressors facing the
immigrant population such as language barriers, social
isolation, unemployment, unstable housing, access to
health care, etc. [9,10].
Our study reports longitudinal measures of HRQOL
over the year following diagnosis, as measured with the
Short Form-36 version 2 (SF-36) questionnaire, reported
by patients recruited from two hospitals in Montreal,
Canada who were treated for TB disease or LTBI
[11,12]. To distinguish the impact of treatment for TB
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disease and LTBI from other stressors related to immi-
gration (e.g. socioeconomic instability and unemploy-
ment), we also include concurrent measures of HRQOL
reported by individuals screened for TB but found not
to require treatment. This participant group remained
untreated throughout the study period.
Our aim was to measure HRQOL of patients treated
for TB disease and LTBI at each milestone of treatment,
along with untreated individuals with a similar socio-
demographic profile to treated participants. These mea-
sures may assist health care professionals understand the
health impact of TB disease, LTBI, and their treatment,
and may inform targeted interventions to improve pa-
tients’ health and well-being.
Methods
Study population and participant recruitment
The study population, sample recruitment, and study de-
sign have been detailed elsewhere [13]. Briefly, study par-
ticipants were recruited between June, 2008 and October,
2011 at two hospitals in Montreal - the Montreal Chest
Institute (MCI) and the Jewish General Hospital (JGH).
Reason for hospital referral of potential participants was
captured at the initial evaluation.
The group of participants diagnosed with TB disease
included patients initially hospitalized and those treated
solely as outpatients; all participants treated for TB dis-
ease had culture-confirmed disease. Participants treated
for LTBI were diagnosed with asymptomatic infection,
typically based on positive results from a tuberculin skin
test (TST) and/or an Interferon-γ Release Assay (IGRA),
and/or presence of scarring on a chest radiograph. Par-
ticipants in the control group were evaluated for pos-
sible TB disease and/or LTBI, and judged not to require
treatment of any kind. All participants were recruited to
the study within two weeks of TB screening/treatment
initiation.
Individuals with multi-drug resistant TB disease, or con-
comitant physical or mental illness likely to affect their
HRQOL were excluded from the study. Furthermore, all
participants were required to understand English or French
and to be at least 18 years of age at study enrollment.
Participants’ written informed consent was obtained
before the initial interview. Research ethics committee
approval was obtained from both the MCI and JGH. The
study was performed in accordance with the ethical
standards established in the 1964 Declaration of Helsinki
and its later amendments.
Study design
Participants were evaluated during clinic or home visits at
1, 2, 4, 6, 9, and 12 months post-baseline, corresponding
to important milestones in TB treatment regimens [4].
We used frequency matching to balance the proportions
of immigrants across the three participant groups; for
every ten participants recruited to the group treated for
TB disease, the proportions of immigrants recruited into
the LTBI and control groups were equalized to the pro-
portion in the TB disease group.
Study measurements
At the baseline interview, participants were evaluated for
language ability and completed questionnaires describing
their socio-demographic and clinical characteristics. In-
cluded in the socio-demographic questionnaire was a
question about immigration status in Canada - Canadian
citizen/permanent resident, immigrant applicant, accepted
refugee, refugee claimant, temporary resident (with an em-
ployment visa), or other category (student or visitor visa).
Clinical information (e.g. diagnostic test results, pre-
scribed treatment regimens, other concomitant condi-
tions and/or medications) was verified in participants’
medical charts at each interview. Participant-reported
changes to medications and adverse events were re-
corded at all follow-up visits and verified in participants’
medical charts.
Participants also completed the written SF-36 ques-
tionnaire, version 2 in Canadian English or Canadian
French at baseline and at all follow-up evaluations [12].
The SF-36 written questionnaire contains 36 questions
and generates scores for 8 domains of HRQOL - phys-
ical functioning, role physical, bodily pain, general
health, vitality, social functioning, role emotional, and
mental health. Physical and mental component summary
(PCS and MCS, respectively) scores can also be derived
from responses [12].
At each interview, the research assistant scanned
the questionnaires for any unanswered questions and
asked the participant to provide missing responses,
unless the question was intentionally left unmarked
by the participant.
We conducted double data entry and resolved discrep-
ancies against paper source documents and by consen-
sus discussion where appropriate.
Main statistical analyses
Socio-demographic characteristics and clinical features
were summarized using descriptive statistics for each
participant group at each assessment. Distributions of
SF-36 domain scores and component summary scores
using an oblique factor solution were summarized for
each participant group at each evaluation [14].
The associations of PCS and MCS scores with partici-
pant group (TB disease, LTBI, control) were the primary
focus of this analysis. Characteristics considered a priori
confounders of these associations were examined quanti-
tatively [15-18]. An a priori level of statistical significance
was set at α = 0.05.
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In addition, an ad hoc analysis was performed stratify-
ing participants treated for TB disease into severe cases
(those hospitalized for treatment of TB disease at base-
line or acid fast smear-positive at baseline) and non-
severe cases (those never hospitalized for TB treatment
and smear-negative at baseline).
Crude effect sizes, examining change in scores over
time within each participant group, were calculated at
each assessment and evaluated using Cohen’s criteria; a
statistically meaningful change in mean scores was de-
fined a priori as an effect size ≥ 0.50 [19].
A minimal clinically important difference (MCID), or
the smallest difference in a domain score which patients
perceive an improvement or a worsening, is unknown in
the TB context [20]. MCID thresholds for SF-36 domain
scores published for patients with other respiratory dis-
eases were compared to our results [21].
Multivariable linear mixed models were used to com-
pare each PCS and MCS score reported by each of the
treated participant groups to the control group, with the
control group as the referent for all models. A time*par-
ticipant group interaction term was included to account
for different score patterns over time between the par-
ticipant groups. Random intercepts, random slopes, and
spatial covariance structures using visit number were in-
corporated into the models. Age at baseline, sex, and
additional factors determined to be important con-
founders were included as covariates in all adjusted
models. Model fit was assessed using the Akaike Infor-
mation Criterion (AIC) [22].
Adjusted estimates of mean PCS and MCS scores for
each participant group at each assessment were calculated
from final model estimates. Changes in adjusted scores be-
tween successive interviews and from baseline were also
calculated from these estimates. Parametric 95% confi-
dence intervals (CI) were calculated for adjusted estimates
of mean scores and changes in mean scores [22].
Sample size calculations were based on the primary ob-
jective of the cohort study – to derive health utility scores
over the year following diagnosis for the three participant
groups [13]. Sample size calculations indicated that 40
participants treated for TB disease should be recruited to
the study to detect a change in health utility scores evalu-
ated with the Standard Gamble of 0.003/month over
12 months with 80% power, ρ = 0.8, and α = 0.05 [13].
Additional information about health utility scores mea-
sured in this cohort is available in reference [13].
Sensitivity analyses
Multiple imputation (MI) was used to quantify the im-
pact of missing data on the final model estimates [23].
Profiles potentially differed between individuals who (1)
agreed to participate vs. those who refused participation,
and (2) those who attended follow-up visits, vs. those who
missed a given visit but returned for later visits, vs. those
permanently lost to follow-up. Age at recruitment/initial
interview and sex were available for all individuals
approached by the research assistant. Individuals in each
diagnosis group were stratified by sex and reason for re-
fusing study participation; mean ages were calculated for
each stratum. Among study participants, we calculated
mean component summary scores according to partici-
pant group, visit number, and attendance status (attended,
missed, or lost to follow-up) at the next scheduled visit.
All statistical analyses were conducted using SAS stat-
istical software (version 9.3; SAS Institute, Cary, North
Carolina, United States); graphs were created using




Of the 568 individuals referred to either the MCI or the
JGH for TB assessment and approached by the research
assistant, 53 (17%) were ineligible for participation at
baseline; of the remainder, 252 refused to participate.
The refusal rate was higher among men (60%) than
women (40%), and among those found not to require
treatment for TB disease or LTBI (67%) compared to
those diagnosed with TB disease (9%) or LTBI (23%). In
total, 263 participants were enrolled in the study - 48
were treated for TB disease, 105 were treated for LTBI,
and 110 were control participants. During follow-up, an
additional 3 participants were determined ineligible for
further participation and were excluded from subsequent
assessments [Figure 1].
Among participants treated for TB disease, 21 (44%)
missed at least one follow-up visit, and 4 (8%) partici-
pants provided data to permit calculation of both PCS
and MCS scores at every follow-up visit. Seventy-six
(72%) participants treated for LTBI and 65 (59%) partici-
pants in the control group missed at least one follow-up
visit. We were able to calculate both PCS and MCS
scores at all visits for 7 (7%) participants treated for
LTBI and 18 (16%) participants in the control group
[Figure 1].
Participant characteristics
Table 1 describes key characteristics reported by partici-
pants at baseline. Fifty-four percent of participants were
women, and 90% of participants were foreign-born;
more than half were Canadian citizens or permanent
residents.
Of the 263 participants, 50% were referred to a study
site for evaluation of a positive TST result, but were not
contacts of persons with TB disease. This group repre-
sented over 60% of the participants treated for LTBI, and
of those in the control group. Fifty percent of the
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participants treated for TB disease were referred to a
study site because of symptoms, and 19% and 15% were
referred for TB screening and surveillance, respectively,
in the context of recent immigration. Sixty-three percent
of participants treated for TB disease missed some work
or school during the study period due to their diagnosis
and treatment [Table 1].
Clinical characteristics are reported in Additional file 1.
Of participants with TB disease, 40 (83%) had pulmonary
disease, of whom 13 (33%) had cavitary disease. Twenty
(42%) received directly observed therapy, and 22 (46%)
were hospitalized; median stay was 14 days (Inter-quartile
range, (IQR) 11, 23).
Among participants treated for LTBI, 20 (19%) had ab-
normal chest radiographs. All participants treated for LTBI
self-administered their medication [Additional file 1].
At the initial assessment, a greater proportion of par-
ticipants treated for TB disease reported at least one
other concomitant health condition (67%) or one other
medication (60%) compared to participants treated for
LTBI (30% and 10%, respectively) or control participants
(12% and 5%, respectively) [Additional file 1].
Sixteen (34%) participants treated for TB disease and 20
(38%) participants treated for LTBI reported at least 1
episode of treatment intolerance between the baseline and
1-month evaluations. These numbers decreased from the
1-month through the 9-month visits. No participant expe-
rienced an adverse event that led to hospitalization.
All participants treated for TB disease completed
treatment. Eighty of the 94 participants (85%) prescribed
the 9-month regimen of INH for the treatment of LTBI
completed their treatment, and 8 of the 10 participants
(80%) prescribed the 4-month regimen of Rifampin for
the treatment of LTBI completed their treatment.
Findings from univariable analyses
Participants treated for TB disease reported somewhat lower
mean PCS scores during the first two months of treatment
and significantly lower mean MCS scores at baseline, com-
pared to other participant groups [Figures 2, 3]. Statistical
Figure 1 Participant selection in longitudinal study with recruitment from June 2008 – October 2011.
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improvement in mean PCS scores was observed from the
2- to the 4-month visits, as indicated by effect sizes ≥ 0.50
[19] [Table 2]. However, mean PCS scores declined
and resembled the mean PCS score at baseline [Table 2,
Figure 2]. Statistical improvements in mean MCS scores
were observed from baseline to each follow-up visit [19]
[Table 3].
At baseline, mean domain scores reported by participants
treated for TB disease were significantly lower than those
reported by other participant groups except for mean men-
tal health scores [Additional file 2]. Significantly lower
mean physical functioning, role physical, and social func-
tioning scores were reported at the 1-month visit by partici-
pants treated for TB disease. This participant group also
reported significantly lower mean general health scores at
the 2-month visit [Additional file 2].
Participants treated for TB disease reported improvement
in mean domain scores from baseline to the 2-month visit
(vitality and mental health), from baseline to the 4-month
visit (role physical), or showed continuous improvement
through the study period. Mean role physical, vitality, and
mental health scores declined during 2 to 6 months of
treatment, but improved again from the 6- to the 9-month
visits [Additional file 2]. Statistical improvements were re-
ported in (1) bodily pain and social functioning from base-
line to each follow-up visit, (2) vitality from baseline to all
follow-up visits except for the 6-month visit, (3) physical
functioning, role physical, role emotional, and mental
health from the baseline to the 2-, 4-, 6-, 9-, and 12-
month visits, and (4) general health from the baseline
to the 9- and 12-month visits [19] [Additional files
4,5,6,7,8,9,10,11].
Mean scores reported by participants treated for
LTBI remained largely comparable with the control
group [Figures 2, 3; Tables 2, 3; Additional files 2, 4,
5,6,7,8,9,10,11].
Table 1 Participant characteristics at the initial interview by participant group and sex (N = 263)
























Sample size 48 (18) 27 (56) 21 (44) 105 (40) 45 (43) 60 (57) 110 (42) 50 (45) 60 (55)
Mean (standard deviation) age - years 37 (12) 38 (15) 36 (7) 33 (9) 34 (9) 33 (10) 35 (8) 34 (8) 35 (8)
Region of origin
Africa 15 (31) 12 (44) 3 (13) 29 (28) 18 (40) 11 (19) 34 (31) 16 (32) 18 (30)
Asia 18 (38) 8 (29) 10 (47) 28 (27) 8 (18) 20 (33) 21 (19) 11 (22) 10 (17)
Eastern Europe 3 (6) 1 (4) 2 (10) 5 (5) 3 (7) 2 (3) 12 (11) 5 (10) 7 (12)
Western Europe 1 (2) 1 (4) 0 (0) 5 (5) 3 (7) 2 (3) 10 (9) 5 (10) 5 (8)
Central America 3 (6) 1 (4) 2 (10) 20 (18) 6 (13) 14 (24) 18 (16) 7 (14) 11 (18)
North America 5 (11) 3 (11) 2 (10) 11 (10) 5 (11) 6 (10) 11 (10) 4 (8) 7 (12)
South America 3 (6) 1 (4) 2 (10) 7 (7) 2 (4) 5 (8) 4 (4) 2 (4) 2 (3)
Median (inter-quartile range) duration in Canada (years) 2 (0–7) 2 (0–10) 2 (0–7) 3 (1–9) 1 (0–6) 5 (2–10) 2 (1–9) 2 (1–7) 2 (1–9)
Reason for hospital referral
Pre-landing refugee or immigrant screening 9 (19) 5 (19) 4 (19) 6 (6) 3 (7) 3 (5) 17 (15) 10 (20) 7 (12)
Post-landing surveillance 7 (15) 3 (11) 4 (19) 11 (10) 7 (16) 4 (7) 7 (6) 4 (8) 3 (5)
Tuberculin Skin Test, not contact of patient with
diagnosed TB disease
1 (2) 0 (0) 1 (5) 64 (61) 22 (49) 42 (70) 67 (61) 27 (54) 40 (67)
Contact of patient with diagnosed TB disease 1 (2) 0 (0) 1 (5) 18 (17) 10 (22) 8 (13) 5 (5) 3 (6) 2 (3)
Symptomatic of TB disease‡ 24 (50) 17 (63) 7 (33) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other 6 (13) 2 (7) 4 (19) 6 (6) 3 (7) 3 (5) 0 (0) 0 (0) 0 (0)
Unknown 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 14 (13) 6 (12) 8 (13)
Smoking status
Ever cigarette smoker* 18 (38) 14 (52) 4 (19) 24 (23) 15 (33) 9 (15) 23 (21) 14 (28) 9 (15)
Current cigarette smoker† 11 (23) 9 (33) 2 (10) 8 (8) 5 (11) 3 (5) 10 (9) 5 (10) 5 (8)
Median (inter-quartile range) pack-years smoking 13 (6–19) 17 (8–20) 5 (3–9) 4 (1–16) 2 (1–16) 5 (2–12) 6 (3–18) 5 (1–18) 6 (4–21)
‡Common symptoms of TB disease include chronic cough of at least two weeks duration, fever, and night sweats. Other symptoms may include hemoptysis,
anorexia, weight loss, and chest pain. *A participant who never smoked is someone who smoked less than 20 packs of cigarettes or 400 grams of tobacco in a
lifetime or less than 1 cigarette a day for 1 year.
†A participant who is a current smoker smoked cigarettes as of 1 month before the initial interview.
Bauer et al. Health and Quality of Life Outcomes  (2015) 13:65 Page 5 of 13
Figure 2 Mean physical component summary scores and 95% confidence intervals from each visit by participant group.
Figure 3 Mean mental component summary scores and 95% confidence intervals from each visit by participant group.
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Participants treated for severe TB disease (26, 54%) re-
ported lower mean scores compared to participants
treated for non-severe TB disease (22, 46%) [Additional
file 3].
Findings from multivariable analyses of component
summary scores
After adjustment, mean PCS scores reported by partici-
pants treated for TB disease did not change significantly
throughout follow-up and were comparable to mean PCS
scores reported by the control group [Table 4, Additional
files 12,13].
The adjusted mean MCS score reported by partici-
pants treated for TB disease was significantly lower than
that reported by the control participants at the initial
interview – mean MCS score reported by participants
treated for TB disease was 46.4 (95% CI: 44.1, 48.8,); the
control group reported a mean MCS score of 51.1 (95%
CI: 48.9, 53.2) [Table 5]. Improvement in adjusted mean
MCS scores was significantly greater among the partici-
pants with TB disease compared to the control partici-
pants, from the baseline to each follow-up visit and from
the 6- to the 9-month visits [Additional files 14,15].
There were no statistically significant differences in ad-
justed mean scores or changes in adjusted scores re-
ported by participants treated for LTBI or the control
group [Tables 4,5; Additional files 12,13,14,15].
Findings from sensitivity analyses
Results of linear mixed model regression including mul-
tiple imputation of missing data yielded similar results
to those of the main models.
There were few differences in mean PCS and MCS
scores among participants who attended, missed, and
who were lost to follow-up; any differences appeared
to be due to random variation [Additional files
16,17,18,19,20,21].
Table 2 Mean physical component summary scores and effect sizes by participant group and sex (N = 205)
Participants Treated for tuberculosis
disease
Treated for latent tuberculosis
infection
Screened for tuberculosis but
healthy and untreated



























Baseline Total 33 49.5 (1.3) - - 81 50.3 (1.1) - - 91 50.2 (0.7) - -
Men 19 (58) 49.6 (1.5) - - 37 (46) 50.2 (0.9) - - 41 (45) 50.1 (0.6) - -
Women 14 (42) 49.4 (1.2) - - 44 (54) 50.4 (1.2) - - 50 (55) 50.3 (0.8) - -
1 month Total 36 49.5 (1.0) 0.0 - 58 50.2 (0.9) −0.1 - 75 50.2 (0.8) 0.0 -
Men 21 (58) 49.6 (1.1) 0.0 - 22 (38) 50.2 (0.6) 0.1 - 38 (51) 50.2 (0.9) 0.2 -
Women 15 (42) 49.4 (0.8) 0.0 - 36 (62) 50.2 (1.1) −0.1 - 37 (49) 50.1 (0.8) −0.2 -
2 months Total 39 49.5 (1.0) 0.0 0.0 52 50.3 (0.8) 0.0 0.1 77 50.1 (0.8) −0.1 0.0
Men 23 (59) 49.7 (1.2) 0.1 0.1 23 (44) 50.2 (0.8) 0.0 0.0 37 (48) 50.1 (0.8) 0.1 0.0
Women 16 (41) 49.2 (0.5) −0.2 −0.2 29 (56) 50.3 (0.8) 0.0 0.1 40 (52) 50.1 (0.8) −0.2 0.0
4 months Total 32 50.1 (1.2) 0.5 0.5 53 50.1 (0.8) −0.2 −0.2 56 50.1 (0.7) −0.1 0.0
Men 19 (59) 50.4 (1.4) 0.6 0.5 26 (49) 50.0 (0.7) −0.2 −0.2 24 (75) 50.2 (0.6) 0.1 0.0
Women 13 (41) 49.6 (0.4) 0.3 0.8 27 (51) 50.1 (0.8) −0.2 −0.2 32 (25) 50.1 (0.7) −0.2 −0.1
6 months Total 33 49.8 (0.6) 0.4 −0.2 44 50.1 (0.7) −0.2 0.0 55 50.1 (0.9) −0.1 −0.1
Men 18 (55) 50.0 (0.6) 0.4 −0.4 25 (57) 50.1 (0.5) −0.1 0.1 27 (49) 50.1 (0.7) 0.0 −0.1
Women 15 (45) 49.7 (0.5) 0.3 0.2 19 (43) 50.0 (0.9) −0.4 −0.2 28 (51) 50. (1.0) −0.2 0.0
9 months Total 30 49.6 (0.8) 0.1 −0.3 37 50.4 (1.0) 0.1 0.3 44 50.0 (1.0) −0.2 −0.1
Men 18 (60) 49.5 (0.9) 0.0 −0.5 20 (54) 50.3 (0.8) 0.2 0.3 18 (44) 49.7 (0.8) −0.5 −0.4
Women 12 (40) 49.8 (0.5) 0.4 0.1 17 (46) 50.4 (1.1) 0.0 0.4 26 (59) 50.2 (1.1) 0.0 0.1
12 months Total 21 49.7 (0.7) 0.2 0.1 42 50.3 (0.9) 0.0 −0.1 49 49.9 (0.7) −0.4 −0.1
Men 13 (62) 49.7 (0.8) 0.2 0.2 21 (50) 50.4 (0.9) 0.2 0.0 23 (47) 50.0 (0.6) −0.2 0.3
Women 8 (38) 49.6 (0.5) 0.2 −0.4 21 (50) 50.2 (0.9) −0.2 −0.2 26 (53) 49.8 (0.8) −0.5 −0.4
Effect size conveys the estimated magnitude in differences in two measures of scores. An effect size ≥0.50 indicates a statistically meaningful change in mean
scores and is indicated in bold font in the table. 15
aEffect Size1 is the effect size of the change in mean physical component summary scores from the baseline visit to the given visit.
bEffect size2 is the effect size of the change in mean physical component summary scores from the previous visit to the given visit, e.g. effect size2 for the
4-month visit is the effect size of the changes in mean physical component summary scores from the 2-month visit to the 4-month visit.
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Discussion
In this longitudinal study among a diverse population
evaluated and/or treated for TB in Montreal, diagnosis
and treatment of TB disease had a significant impact on
HRQOL as measured by the SF-36, particularly with re-
spect to its mental aspects. MCS scores improved
throughout the study period, while PCS scores improved
slightly from the 2- to the 4-month visits and declined
again during the remainder of follow-up. At baseline, most
domain scores among participants treated for TB disease
were significantly lower than those among other partici-
pant groups. Domain scores reported by those treated for
TB disease generally improved throughout follow-up.
Diagnosis and treatment for LTBI, on the other hand,
had a minimal impact on HRQOL throughout the study
period – mean scores reported by participants treated for
LTBI were generally comparable to those reported by the
control group.
Normative PCS and MCS scores for the Canadian
population are 50.5 and 51.7, respectively [26]. Mean
PCS scores reported by participants treated for TB dis-
ease in our study were similar to the Canadian norma-
tive PCS score. MCS scores among participants with TB
disease were lower than Canadian values at baseline, but
exceeded Canadian norms by the end of follow-up.
Scores among participants treated for LTBI and control
participants were similar to Canadian norms. The theory
of social support proposes that support contributes to
health by protecting people from the adverse effects of
stress [27]. The majority of our study participants
treated for TB disease were foreign-born persons who
had arrived in Canada within the last 2–5 years. They
may have experienced stresses related to immigration
and/or social isolation in addition to those related to TB
diagnosis and treatment. Providing additional support
targeted at these stressors as part of TB care, especially
Table 3 Mean mental component summary scores and effect sizes by participant group and sex (N = 205)
Participants Treated for tuberculosis disease Treated for latent tuberculosis
infection
Screened for tuberculosis but
healthy and untreated



























Baseline Total 33 47.2 (6.5) - - 81 50.6 (4.7) - - 91 51.7 (4.3) - -
Men 19 (58) 46.7 (7.6) - - 37 (46) 52.0 (3.2) - - 41 (45) 52.8 (3.5) - -
Women 14 (42) 48.0 (4.9) - - 44 (54) 49.4 (5.4) - - 50 (55) 50.7 (4.8) - -
1 month Total 36 50.9 (5.6) 0.6 - 58 50.1 (5.2) −0.1 - 75 52.0 (4.3) 0.1 -
Men 21 (58) 49.6 (5.4) 0.4 - 22 (38) 51.6 (3.9) −0.1 - 38 (51) 52.0 (4.3) −0.2 -
Women 15 (42) 52.8 (5.5) 0.9 - 36 (62) 49.3 (5.6) 0.0 - 37 (49) 51.9 (4.3) 0.3 -
2 months Total 39 52.2 (4.6) 0.9 0.3 52 51.0 (4.7) 0.1 0.2 77 52.1 (4.1) 0.1 0.0
Men 23 (59) 51.0 (4.9) 0.7 0.3 23 (44) 52.4 (2.9) 0.1 0.2 37 (48) 52.6 (4.0) −0.1 0.1
Women 16 (41) 54.1 (3.5) 1.4 0.3 29 (56) 49.8 (5.5) 0.1 0.1 40 (52) 51.6 (4.3) 0.2 −0.1
4 months Total 32 50.8 (6.6) 0.5 −0.3 53 51.1 (4.2) 0.1 0.0 56 52.1 (3.4) 0.1 0.0
Men 19 (59) 49.1 (7.4) 0.3 −0.3 26 (49) 52.5 (3.6) 0.1 0.0 24 (43) 52.0 (3.6) −0.2 −0.1
Women 13 (41) 53.2 (4.4) 1.1 −0.2 27 (51) 49.8 (4.4) 0.1 0.0 32 (57) 52.1 (3.3) 0.3 0.1
6 months Total 33 51.5 (5.8) 0.7 0.1 44 51.5 (3.9) 0.2 0.1 55 51.9 (4.1) 0.1 0.0
Men 18 (55) 50.9 (5.9) 0.6 0.3 25 (57) 52.5 (2.6) 0.2 0.0 27 (49) 52.0 (3.8) −0.2 0.0
Women 15 (45) 52.2 (5.7) 0.8 −0.2 19 (43) 50.2 (5.0) 0.1 0.1 28 (51) 51.7 (4.5) 0.2 −0.1
9 months Total 30 53.6 (3.5) 1.2 0.4 37 50.9 (4.8) 0.1 −0.1 44 52.0 (5.3) 0.1 0.0
Men 18 (60) 53.2 (4.1) 1.1 0.5 20 (54) 51.6 (3.8) −0.1 −0.3 18 (41) 53.4 (2.7) 0.2 0.4
Women 12 (40) 54.0 (2.6) 1.5 0.4 17 (46) 50.2 (5.7) 0.1 0.0 26 (59) 50.9 (6.4) 0.0 −0.1
12 months Total 21 54.3 (2.9) 1.4 0.2 42 51.3 (4.5) 0.1 0.1 49 52.9 (4.1) 0.3 0.2
Men 13 (62) 53.9 (2.4) 1.3 0.2 21 (50) 51.2 (4.4) −0.2 −0.1 23 (47) 53.2 (2.8) 0.1 −0.1
Women 8 (38) 54.8 (3.7) 1.6 0.3 21 (50) 51.4 (4.7) 0.4 0.2 26 (53) 52.5 (5.0) 0.4 0.3
Effect size conveys the estimated magnitude in differences in two measures of scores. An effect size ≥0.50 indicates a statistically meaningful change in mean
scores and is indicated in bold font in the table15.
aEffect Size1 is the effect size of the change in mean mental component summary scores from the baseline visit to the given visit.
bEffect size2 is the effect size of the change in mean mental component summary scores from the previous visit to the given visit, e.g. effect size2 for the 4-month
visit is the effect size of the changes in mean mental component summary scores from the 2-month visit to the 4-month visit.
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at diagnosis and early in the treatment regimen, may im-
prove HRQOL, particularly mental well-being.
The evolution of scores among participants treated for
TB disease likely reflects both actual changes in physical
and/or mental well-being over time, and response shift,
i.e. changes in internal standards, values, and/or prior-
ities [28]. Changes observed in mean MCS scores may
be due to due to true change as well as response shift.
Future analyses will examine the impact of potential re-
sponse shift on reported HRQOL.
MCID thresholds are not known in the TB context,
but are published for patients with other respiratory dis-
eases [20.21]. Wyrwich et. al. (2005) calculated ranges of
change across the eight domains of the SF-36 for patients
treated for chronic obstructive pulmonary disease that indi-
cated small change (8.3 – 12.5), moderate change (16.7 –
25), and large change (25 – 37.5). Corresponding figures
for patients treated for asthma were 10 – 16.7, 20 – 33.3,
and 30 – 50, respectively [21]. Mean improvements in do-
main scores reported by participants treated for TB disease,
from the initial to the 12-month assessment, ranged from
+10.3 points (general health) to +44.7 points (social func-
tioning), suggesting small, moderate, and large changes
across the domains of the SF-36.
Four other studies report PCS and MCS scores of pa-
tients treated for TB disease within two weeks of treat-
ment initiation [2,11,29,30]. Mean component summary
scores reported by our participants treated for TB disease
were similar to those reported in our previous pilot study
in Montreal (mean PCS score = 53, mean MCS score =
49), and to those described in a cohort treated for TB dis-
ease in Vancouver, Canada (mean PCS score = 48, mean
MCS score = 43) [2,11]. A cohort treated for TB disease in
London, the United Kingdom reported lower mean PCS
(36) and MCS (42) scores, while a group treated for TB
disease in Uganda reported higher scores; mean PCS and
MCS scores were 61 [29,30].
Similar to our findings, Kruijshaar et. al. reported im-
provement in mean MCS but not mean PCS scores from
diagnosis to two months of treatment among patients
treated for TB disease in London, the United Kingdom
[1,29]. However, Marra et. al. did not find any significant
improvement in mean PCS or MCS scores from diagno-
sis to six months of treatment among participants
treated for TB disease in Vancouver [1,2].
Many factors may contribute to the similarities and
differences observed between our findings and the re-
sults reported by other studies. It is not surprising
that results in two Canadian cities (Montreal and
Vancouver) were generally comparable. However, al-
though most persons treated for TB in London and
in Canadian cities are immigrants, their demograph-
ics, views, and experiences may differ. HRQOL and
TB are interpreted differently across cultures and
Table 4 Mean physical component summary scores










Tuberculosis disease 49.5 50.0 49.5 - 50.5 0.001*
Latent tuberculosis
infection
50.3 50.6 50.3 - 51.0 0.37
Controlb 50.2 50.7 50.1 - 51.2 -
1 month of treatment
Tuberculosis disease 49.5 49.9 49.4 - 50.5 0.90
Latent tuberculosis
infection
50.2 50.5 50.1 - 50.9 0.98
Control 50.2 50.7 50.1 - 51.3 -
2 months of treatment
Tuberculosis disease 49.5 50.0 49.4 - 50.5 0.45
Latent tuberculosis
infection
50.3 50.6 50.2 - 51.0 0.95
Control 50.2 50.8 50.3 - 51.3 -
4 months of treatment
Tuberculosis disease 50.0 50.4 49.8 - 51.0 0.89
Latent tuberculosis
infection
50.1 50.4 50.0 - 50.8 0.90
Control 50.1 50.8 50.2 - 51.5 -
6 months of treatment
Tuberculosis disease 49.7 50.2 49.7 - 50.7 0.89
Latent tuberculosis
infection
50.1 50.5 50.0 - 50.9 0.96
Control 50.1 50.8 50.3 - 51.4 -
9 months of treatment
Tuberculosis disease 49.6 49.9 49.3 - 50.5 0.09
Latent tuberculosis
infection
50.3 50.6 50.2 - 51.1 0.90
Control 50.1 51.1 50.5 - 51.8 -
12 months of treatment
Tuberculosis disease 49.6 50.1 49.5 - 50.6 0.04*
Latent tuberculosis
infection
50.2 50.6 50.1 - 51.0 0.50
Control 50.0 50.7 50.1 - 51.3 -
aAdjusted models comparing participants treated for tuberculosis disease to
those participants in the untreated control group controlled for age at
baseline, sex, other medication exposures at baseline (yes/no) reported in
medical charts, and number of individuals residing in participants’ households.
Adjusted models comparing participants treated for latent tuberculosis
infection to those participants in the untreated control group controlled for
age at baseline and sex.
bControl is a participant screened for tuberculosis who tested negative for
tuberculosis and was found not to require treatment.
*Indicates a p-value less than 0.05 meaning a statistically significant difference
in mean physical component summary scores reported by the group of
treated participants and the participants in the control group in the adjusted
model, at the given visit.
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settings, which may also explain differences with the
results from the Ugandan study.
As expected, participants in our study treated for more
severe TB disease reported somewhat poorer HRQOL
compared to those treated for non-severe TB disease.
However, this analysis should be interpreted cautiously
given the small size of these sub-groups.
Our study is the first to concurrently evaluate HRQOL
of individuals treated for TB disease, LTBI, and an un-
treated comparison group at each milestone of treat-
ment. The control group, with a similar demographic
profile to the other participant groups, helps tease apart
the impact of diagnosis and treatment for TB disease and
LTBI from other stressors, most notably those related to
immigration. As such, decrements in HRQOL reported by
participants treated for TB disease are likely related to the
diagnosis and treatment of this disease rather than to ex-
ternal stressors. The fact that participants treated for se-
vere TB disease reported the poorest mean scores for
physical health domains is consistent with this premise.
There are several limitations of our study, beginning
with our inability to document HRQOL while persons
were ill with TB disease, but not yet diagnosed. This
would tend to underestimate the impact of symptomatic
TB disease on HRQOL. Previous studies of symptomatic
patients diagnosed with TB disease estimate that on
average, such individuals experience symptoms for three
months before diagnosis; the interval is substantially lon-
ger in resource-limited settings [31,32].
Selection bias may also have affected our estimates of
HRQOL. First, participation in this study required English
or French language skills. Second, we had very little data
to characterize individuals who refused to participate.
Third, participants who missed visits or who were lost to
follow-up are of particular concern among participants
treated for LTBI, as those who experienced disruptive
treatment side effects may have stopped their medication
and follow-up visits. However, our sensitivity analyses in-
dicated comparable mean PCS and MCS scores among
participants who subsequently attended visits, missed
visits, or who were lost to follow-up.
Our study was conducted in a low TB disease inci-
dence setting with an overwhelming majority of immi-
grants. Some high-risk groups (immigrants without
English or French language skills, and Aboriginal peo-
ples) were not well-represented in this study. Our re-
sults, therefore, may not be generalizable to high-
incidence, resource-limited settings and to groups un-
derrepresented in this study.
Finally, our analysis was limited in that we did not use
a mixed methods approach; we did not collect qualita-
tive data to expand on the findings of this quantitative
analysis. Recent findings from qualitative interviews of
patients treated for TB disease suggest a similar negative
Table 5 Mean mental component summary scores










Tuberculosis disease 47.1 46.4 44.1 - 48.8 <0.01*
Latent tuberculosis
infection
50.5 50.5 48.5 - 52.4 0.07
Controlb 51.7 51.1 48.9 - 53.2 -
1 month of treatment
Tuberculosis disease 50.7 50.1 47.5 - 52.6 0.69
Latent tuberculosis
infection
50.2 50.2 48.0 - 52.3 0.72
Control 51.5 50.8 48.6 - 53.1 -
2 months of treatment
Tuberculosis
disease
51.8 51.3 48.8 - 53.7 0.75
Latent tuberculosis
infection
50.5 50.6 48.5 - 52.8 0.86
Control 51.7 51.2 49.2 - 53.2 -
4 months of treatment
Tuberculosis disease 50.8 50.3 47.7 - 52.9 0.67
Latent tuberculosis
infection
50.9 51.0 48.8 - 53.1 0.67
Control 51.9 51.4 49.1 - 53.8 -
6 months of treatment
Tuberculosis disease 51.7 51.2 48.6 - 53.8 0.50
Latent tuberculosis
infection
50.7 50.7 48.5 - 53.0 0.52
Control 51.5 51.0 48.7 - 53.4 -
9 months of treatment
Tuberculosis disease 54.0 53.6 50.9 - 56.4 0.88
Latent tuberculosis
infection
50.5 50.5 48.1 - 52.9 0.71
Control 51.4 51.0 48.5 - 53.5 -
12 months of treatment
Tuberculosis disease 54.0 53.6 50.7 - 56.5 0.28
Latent tuberculosis
infection
50.9 50.9 48.6 - 53.2 0.30
Control 52.2 51.7 49.3 - 54.2 -
aAdjusted models comparing participants treated for tuberculosis disease to
those participants in the untreated control group controlled for age at
baseline and sex. Adjusted models comparing participants treated for latent
tuberculosis infection to those participants in the untreated control group
controlled for age at baseline and sex.
bControl is a participant screened for tuberculosis who tested negative for
tuberculosis and was found not to require treatment.
*Indicates a p-value less than 0.05 meaning a statistically significant difference
in mean mental component summary scores reported by the group of treated
participants and the participants in the control group in the adjusted model,
at the given visit.
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impact of TB disease and diagnosis, particularly on men-
tal well-being, as we found in our quantitative analysis
[33-35]. Future research should consider capturing pa-
tient perspectives using both quantitative and qualitative
approaches.
Conclusion
We observed a significant negative impact of TB disease
on HRQOL in a diverse sample of patients treated in
Montreal. While all domains were affected, the greatest
impact was on mental health dimensions, which improved
throughout the study period. The diagnosis and treatment
of LTBI had little effect on HRQOL.
Our results highlight impaired mental well-being but
unaltered physical well-being of participants treated for
TB disease, particularly in the early months of treatment.
These findings suggest a potential role for targeted, cul-
turally relevant psychosocial support interventions for
persons treated for TB disease, especially during the
early months of treatment. For example, participants
treated for TB disease reported particular decrements in
social functioning early in treatment [Additional file 2].
Based on this finding, health care policy makers may
want to focus on ending respiratory isolation as soon as
possible and offer supportive services that integrate pa-
tients back into their communities as quickly as possible.
In this way, our results may be used to guide health care
professionals and health care policy makers in designing
new approaches to patient care that address gaps in the
well-being of persons treated for TB disease in Canada.
Additional files
Additional file 1: Table S1. Clinical characteristics at the initial
interview by participant group and sex. Data describes diagnostic test
results, measures of disease severity, treatment regimens, and treatment
administration, stratified by participant group and sex.
Additional file 2: Figure S1. Mean domain scores and 95% confidence
intervals reported at each visit by participant group. Mean scores and
95% confidence intervals of each of the eight domains of the SF-36
questionnaire as reported by each participant group at each visit.
Additional file 3: Figure S2. Mean SF-36 summary component scores
and domain scores and 95% confidence intervals reported at each visit
by participants treated for tuberculosis disease, stratified by disease
severity. Mean scores and 95% confidence intervals of the two summary
component scores and eight domains of the SF-36 questionnaire as
reported at each visit by (1) participants treated for severe TB disease,
and (2) participants treated for non-severe TB disease.
Additional file 4: Table S4. Mean physical functioning scores and
effect sizes at each follow-up visit by participant group and sex (N = 258).
Mean SF-36 physical functioning scores and standard deviations reported
at each visit, stratified by participant group and sex. Two effect size
measures were calculated for each stratum: (1) the effect size between
mean scores from baseline to each follow-up visit, and (2) the effect size
between mean scores from a given visit to the next consecutive visit.
Additional file 5: Figure S5. Mean role physical scores and effect sizes
at each follow-up visit by participant group and sex (N = 258). Mean SF-36
role physical scores and standard deviations reported at each visit, stratified
by participant group and sex. Two effect size measures were calculated for
each stratum: (1) the effect size between mean scores from baseline to each
follow-up visit, and (2) the effect size between mean scores from a given
visit to the next consecutive visit.
Additional file 6: Table S6. Mean bodily pain scores and effect sizes at
each follow-up visit by participant group and sex (N = 219). Mean SF-36
bodily pain scores and standard deviations reported at each visit, stratified
by participant group and sex. Two effect size measures were calculated for
each stratum: (1) the effect size between mean scores from baseline to each
follow-up visit, and (2) the effect size between mean scores from a given
visit to the next consecutive visit.
Additional file 7: Table S7. Mean general health scores and effect sizes
at each follow-up visit by participant group and sex (N = 258). Mean SF-36
general health scores and standard deviations reported at each visit,
stratified by participant group and sex. Two effect size measures were
calculated for each stratum: (1) the effect size between mean scores from
baseline to each follow-up visit, and (2) the effect size between mean scores
from a given visit to the next consecutive visit.
Additional file 8: Table S8. Mean vitality scores and effect sizes at each
follow-up visit by participant group and sex (N = 253). Mean SF-36 vitality
scores and standard deviations reported at each visit, stratified by participant
group and sex. Two effect size measures were calculated for each stratum:
(1) the effect size between mean scores from baseline to each follow-up
visit, and (2) the effect size between mean scores from a given visit to the
next consecutive visit.
Additional file 9: Table S9. Mean social functioning scores and effect
sizes at each follow-up visit by participant group and sex (N = 258). Mean
SF-36 social functioning scores and standard deviations reported at each
visit, stratified by participant group and sex. Two effect size measures were
calculated for each stratum: (1) the effect size between mean scores from
baseline to each follow-up visit, and (2) the effect size between mean scores
from a given visit to the next consecutive visit.
Additional file 10: Table S10. Mean role emotional scores and effect
sizes at each follow-up visit by participant group and sex (N = 258). Mean
SF-36 role emotional scores and standard deviations reported at each
visit, stratified by participant group and sex. Two effect size measures
were calculated for each stratum: (1) the effect size between mean scores
from baseline to each follow-up visit, and (2) the effect size between
mean scores from a given visit to the next consecutive visit.
Additional file 11: Table S11. Mean mental health scores and effect
sizes at each follow-up visit by participant group and sex (N = 256). Mean
SF-36 mental health scores and standard deviations reported at each visit,
stratified by participant group and sex. Two effect size measures were
calculated for each stratum: (1) the effect size between mean scores from
baseline to each follow-up visit, and (2) the effect size between mean
scores from a given visit to the next consecutive visit.
Additional file 12: Table S12. Changes in mean physical component
summary scores reported since the baseline visit to each follow-up visit
by each participant group. Using linear mixed models and controlling for
important confounders, these data present changes in mean SF-36
physical component summary scores (both crude and adjusted estimates)
from baseline to each follow-up visit. The 95% confidence intervals of
adjusted estimates are presented in this file, along with p-values
indicating the statistical significance of the difference in adjusted
estimates between each of the treated participant groups and the control
group at each time interval.
Additional file 13: Table S13. Changes in mean physical component
summary scores reported at each follow-up interval by each participant
group. Using linear mixed models and controlling for important
confounders, these data present changes in mean SF-36 physical
component summary scores (both crude and adjusted estimates) from a
given visit to each consecutive follow-up visit. The 95% confidence intervals
of adjusted estimates are presented in this file, along with p-values
indicating the statistical significance of the difference in adjusted estimates
between each of the treated participant groups and the control group at
each time interval.
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Additional file 14: Table S14. Changes in mean mental component
summary scores reported since the baseline visit to each follow-up visit
by each participant group. Using linear mixed models and controlling for
important confounders, these data present changes in mean SF-36
mental component summary scores (both crude and adjusted estimates)
from baseline to each follow-up visit. The 95% confidence intervals of
adjusted estimates are presented in this file, along with p-values indicating the
statistical significance of the difference in adjusted estimates between each of
the treated participant groups and the control group at each time interval.
Additional file 15: Table S15. Changes in mean mental component
summary scores reported at each follow-up interval by each participant
group. Using linear mixed models and controlling for important
confounders, these data present changes in mean SF-36 mental component
summary scores (both crude and adjusted estimates) from a given visit to
each consecutive follow-up visit. The 95% confidence intervals of adjusted
estimates are presented in this file, along with p-values indicating the statistical
significance of the difference in adjusted estimates between each of the
treated participant groups and the control group at each time interval.
Additional file 16: Table S16. Adjusted mean SF-36 physical component
summary scores calculated using multiple imputation, reported at each
follow-up visit by participant group. Using linear mixed models and controlling
for important confounders, these data present adjusted estimates of mean
SF-36 physical component summary scores (calculated using multiple
imputation) reported at each visit for each participant group. The 95%
confidence intervals of the adjusted estimates are also shown, along with
p-values indicating the statistical significance of the difference in adjusted
estimates between each of the treated participant groups and the control
group at each visit.
Additional file 17: Table S17. Adjusted changes in mean SF-36 physical
component summary scores calculated using multiple imputation reported
since the baseline visit to each follow-up interval, by each participant group.
Using linear mixed models and controlling for important confounders, these
data present adjusted estimates of changes in mean SF-36 physical
component summary scores (calculated using multiple imputation) reported
from the baseline visit to each follow-up visit, for each participant group.
The 95% confidence intervals of the adjusted estimates are also shown,
along with p-values indicating the statistical significance of the difference in
adjusted estimates between each of the treated participant groups and the
control group at each time interval.
Additional file 18: Table S18. Adjusted changes in mean SF-36 physical
component summary scores calculated using multiple imputation reported
at each follow-up interval, by participant group. Using linear mixed models
and controlling for important confounders, these data present adjusted
estimates of changes in mean SF-36 mental component summary scores
(calculated using multiple imputation) reported from a given visit to each
consecutive follow-up visit, for each participant group. The 95% confidence
intervals of the adjusted estimates are also shown, along with p-values
indicating the statistical significance of the difference in adjusted estimates
between each of the treated participant groups and the control group at
each time interval.
Additional file 19: Table S19. Adjusted mean SF-36 mental component
summary scores calculated using multiple imputation, reported at each
follow-up visit by participant group. Using linear mixed models and controlling
for important confounders, these data present adjusted estimates of mean
SF-36 mental component summary scores (calculated using multiple
imputation) reported at each visit for each participant group. The 95%
confidence intervals of the adjusted estimates are also shown, along with
p-values indicating the statistical significance of the difference in adjusted
estimates between each of the treated participant groups and the control
group at each visit.
Additional file 20: Table S20. Adjusted changes in mean SF-36 mental
component summary scores calculated using multiple imputation reported
since the baseline visit to each follow-up interval, by each participant group.
Using linear mixed models and controlling for important confounders, these
data present adjusted estimates of changes in mean SF-36 mental component
summary scores (calculated using multiple imputation) reported from the
baseline visit to each follow-up visit, for each participant group. The 95%
confidence intervals of the adjusted estimates are also shown, along with
p-values indicating the statistical significance of the difference in adjusted
estimates between each of the treated participant groups and the control
group at each time interval.
Additional file 21: Table S21. Adjusted changes in mean SF-36 mental
component summary scores calculated using multiple imputation reported
at each follow-up interval, by participant group. Using linear mixed models
and controlling for important confounders, these data present adjusted
estimates of changes in mean SF-36 mental component summary scores
(calculated using multiple imputation) reported from a given visit to each
consecutive follow-up visit, for each participant group. The 95% confidence
intervals of the adjusted estimates are also shown, along with p-values
indicating the statistical significance of the difference in adjusted estimates
between each of the treated participant groups and the control group at
each time interval.
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